Ascoril exponent (Ascoril expectorant)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Active substanceBromhexine + Guaifenesin + SalbutamolBromhexine + Guaifenesin + Salbutamol
Similar drugsTo uncover
  • Ascoril
    pills inwards 
    Glenmark Pharmaceuticals Co., Ltd.     India
  • Ascoril exponent
    syrup inwards 
    Glenmark Pharmaceuticals Co., Ltd.     India
  • Cofisme
    syrup inwards 
    Agio Pharmaceuticals Ltd.     India
    • Dosage form: & nbspsyrup
    Composition:

    Every 10 ml of syrup contains:

    Active substances:

    Salbutamol sulfate, equivalent to salbutamol - 2.00 mg,

    Bromhexine hydrochloride is 4.00 mg,

    Guaifenesin - 100.00 mg;

    Excipients: sucrose (sugar), sorbitol (70% solution), glycerol (glycerin), propylene glycol, sodium benzoate, citric acid monohydrate, sorbic acid, dye sunset yellow (FCF), menthol (levomenthol), black currant flavor (perfume black currant ID 20158), Pineapple Flavor (Pineapple Super Super "PH"), purified water.

    Description:Transparent, orange, a viscous liquid with a specific odor.
    Pharmacotherapeutic group:Expectorant combination
    ATX: & nbsp

    R.05.C   Expectorants (excluding combinations with antitussive drugs)

    Pharmacodynamics:

    The combined preparation has a bronchodilator, expectorant and mucolytic effect. Salbutamol - a bronchodilator, stimulates beta2-adrenoreceptors of bronchi, blood vessels and myometrium. Warns or eliminates spasm of the bronchi, reduces resistance in the airways, increases the vital capacity of the lungs. Causes the expansion of the coronary arteries, does not reduce blood pressure. Bromhexine is a mucolytic agent. Has an expectorant effect, improves sputum discharge. Guaifenesin - mucolytic agent, reduces the surface tension of the bronchopulmonary structures; stimulates the secretory cells of the bronchial mucosa that produce neutral polysaccharides, depolymerizes acidic mucopolysaccharides, reduces the viscosity of phlegm, facilitates the removal of sputum and facilitates the transition of non-productive cough to productive.

    Pharmacokinetics:

    Salbutamol: when absorbed, absorption is high. Eating reduces the absorption rate, but does not affect bioavailability. Connection with plasma proteins - 10%. Penetrates through placenta.

    It is subjected to presystemic metabolism in the liver and in the intestinal wall, by means of phenol sulfotransferase is inactivated to 4-o-sulfate ether. The half-life (T1 / 2) is 3.8-6 hours.It is excreted by the kidneys (69-90%), mainly in the form of an inactive phenol sulfate metabolite (60%) for 72 hours and with bile (4%). The bioavailability of orally administered salbutamol is about 50%.

    Bromhexine: When ingested almost completely (99%) is absorbed in the gastrointestinal tract (GIT) for 30 minutes. Bioavailability is low (the effect of primary "passage" through the liver). Penetrates through the placental and blood-brain barrier. In the liver it is demethylated and oxidized, metabolized to pharmacologically active ambroxol. T1 / 2 -15 h (due to slow reverse diffusion from tissues). It is excreted by the kidneys. With chronic renal failure, excretion of metabolites is impaired. With multiple applications can cumulate.

    Guaifenesin: absorption from the gastrointestinal tract - fast (after 25-30 minutes after ingestion). T1 / 2 -1h. Penetrates into tissues containing acidic mucopolysaccharides.

    Approximately 60% of the injected drug is metabolized in the liver. It is excreted by lungs (with phlegm) and kidneys both in unchanged form and in the form of inactive metabolites.

    Indications:

    As a part of the combined therapy of acute and chronic bronchopulmonary diseases, accompanied by the formation of a hard-to-separate viscous secretion:

    - bronchial asthma;

    - tracheobronchitis;

    - obstructive bronchitis;

    - pneumonia;

    - emphysema of the lungs;

    - whooping cough;

    - pneumoconiosis;

    - pulmonary tuberculosis, etc.

    Contraindications:

    - Pincreased sensitivity to the components of the drug;

    - pregnancy, lactation;

    - tachyarrhythmia, myocarditis;

    - heart defects;

    - Decompensated diabetes mellitus;

    - thyrotoxicosis; glaucoma;

    - hepatic or renal insufficiency;

    - peptic ulcer of the stomach and duodenum in the stage of exacerbation.

    Carefully:

    Diabetes mellitus, arterial hypertension, peptic ulcer of the stomach and duodenum in remission.

    Pregnancy and lactation:

    The drug is contraindicated during pregnancy and lactation.

    Dosing and Administration:

    Inside. Adults and children over 12 years are prescribed 10 ml (2 teaspoons) 3 times / day. Children under the age of 6 years - 5 ml (1 teaspoon) 3 times / day, 6 to 12 years - 5-10 ml (1-2 teaspoons) 3 times / day. Shake before use.

    Side effects:

    Rarely: when used in high doses, sometimes headache, dizziness, increased nervous excitability, sleep disturbance, drowsiness, tremor, convulsions, nausea, vomiting, diarrhea,exacerbation of peptic ulcer of the stomach and duodenum, palpitation, it is possible to stain urine pink, allergic reactions (rash, urticaria), collapse, bronchospasm.

    Overdose:

    Symptoms: increased manifestations of side effects, except for dose-dependent allergic reactions.

    Treatment: symptomatic therapy.

    Interaction:

    Other beta2-adrenomimetic agents and theophylline increase the effect of salbutamol and increase the likelihood of side effects.

    Ascoril ekspektorant not appointed simultaneously with drugs containing codeine, and other antitussive agents, as this makes it difficult to move away diluted sputum.

    Included in the composition of the drug Ascoril ekspectorant bromohexine contributes to the penetration of antibiotics (erythromycin, cephalexin, oxytetracycline) into the lung tissue.

    It is not recommended to use Ascoril Expectorant at the same time as nonselective beta-adrenergic receptor blockers, such as propranolol.

    Included in the composition of the drug Ascoril ekspectorant salbutamol It is not recommended for patients who receive monoamine oxidase inhibitors (MAO).

    Diuretics and preparations of glucocorticosteroids increase the hypokalemic effect of salbutamol.

    Alkaline drink is not recommended at the same time as Askoryl.

    Form release / dosage:

    Syrup.

    Packaging:

    To 100 ml or 200 ml in a plastic bottle of dark color with a screwed aluminum cover with the control of the first opening, on which a plastic measuring cap of white color or transparent plastic measuring cup with logo "G" and multi-colored risks (green for 2.5 ml, yellow for 5.0 ml and red for 10.0 ml). Each vial with the instruction for use is placed in a cardboard box.

    Storage conditions:

    List B.

    In a dry, dark place at a temperature of no higher than 25 0 FROM.

    Keep out of the reach of children.

    Shelf life:

    2 years.

    Do not use after the expiration date.

    Terms of leave from pharmacies:On prescription
    Registration number:П N015290 / 01
    Date of registration:13.08.2008 / 04.08.2016
    Expiration Date:Unlimited
    The owner of the registration certificate:Glenmark Pharmaceuticals Co., Ltd.Glenmark Pharmaceuticals Co., Ltd. India
    Manufacturer: & nbsp
    Representation: & nbspGLENMARK IMPEX LLCGLENMARK IMPEX LLCRussia
    Information update date: & nbsp19.09.2017
    Illustrated instructions
      Instructions
      Up